Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.86 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251960 | 0.88 | DHODH (0.79) | DHODHNR4A2 | |
| SCHEMBL253507 | 0.88 | DHODH (0.78) | DHODHNR4A2 | |
| SCHEMBL3914908 | 0.87 | DHODH (0.77) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL502677 | 0.87 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL245748 | 0.87 | DHODH (0.77) | DHODHNR4A2 | |
| SCHEMBL254108 | 0.86 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL252035 | 0.83 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL503380 | 0.83 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL3924727 | 0.82 | DHODH (0.84) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL249278 | 0.81 | DHODH (0.69) | DHODHNR4A2JMJD7NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | claimed |
| US-10646478-B2 | Methods for treatment of melanoma | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190117635-A1 | METHODS FOR TREATMENT OF MELANOMA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-04-25 | — | — | US | disclosed |
| US-10016402-B2 | Methods for treatment of melanoma | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016402-B2 | Methods for treatment of melanoma | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2966058-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2966058-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2966058-A1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1392642-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006425-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | DHODH 1/4885NR4A2 800/4885JMJD7 1570/4885 |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, HADHA | DHODH 1/4885NR4A2 587/4885JMJD7 1086/4885 |
| US-10646478-B2 | Methods for treatment of melanoma | DHODH, ALDH1A2, DLD | DHODH 1/4885NR4A2 2334/4885JMJD7 1770/4885 |
| US-20190117635-A1 | METHODS FOR TREATMENT OF MELANOMA | DHODH, ALDH1A2, DLD | DHODH 1/4885NR4A2 2334/4885JMJD7 1770/4885 |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885NR4A2 2728/4885JMJD7 2925/4885 |
| US-10016402-B2 | Methods for treatment of melanoma | DHODH, ALDH1A2, DLD | DHODH 1/4885NR4A2 2334/4885JMJD7 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.